News - Boehringer Ingelheim, Roche


Current filters:

Boehringer IngelheimRoche

Popular Filters

Greater brand-drug adoption fuels Asia-Pacific breast cancer market


Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics…

afatinibAsia-PacificBoehringer IngelheimEisaiHalavenKadcylaMarkets & MarketingneratinibOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

More highlights from European Cancer Congress from Boehringer and Roche

More highlights from European Cancer Congress from Boehringer and Roche


Roche presented new results from a trial of an investigational antibody which have shown encouraging…

Boehringer IngelheimEuropeHerceptinnintedanibOncologyPharmaceuticalResearchRoche

Boehringer Ingelheim's Gilotrif could be leading therapy if it overcomes concerns, says GlobalData


Family-owned German drug major Boehringer Ingelheim could face "significant challenges" over its first-line…

AstraZenecaBoehringer IngelheimEuropeGilotrifIressaMarkets & MarketingOncologyPharmaceuticalRocheTarceva

US FDA approves companion diagnostic for Tarceva, and new indication for the Roche drug


The US Food and Drug Administration late yesterday (May 14) approved Swiss drug major Roche (ROG: SIX)…

Boehringer IngelheimNorth AmericaOncologyPharmaceuticalQiagenRegulationRocheTarcevaTomtovok

Flood of new cancer drug data presented at ASCO; nearly 1,000 being tested


The annual prestigious American Society of Clinical Oncology (ASCO) meeting taking place in Chicago,…

afatinibBiotechnologyBoehringer IngelheimGenentechJanssenJohnson & JohnsonOncologyPharmaceuticalResearchRochetrastuzumab emtansineZytiga

Back to top